<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref027">
 <label>27</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Grebely</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Dore</surname>
   <given-names>GJ</given-names>
  </name>, 
  <name>
   <surname>Alami</surname>
   <given-names>NN</given-names>
  </name>, 
  <name>
   <surname>Conway</surname>
   <given-names>B</given-names>
  </name>, 
  <name>
   <surname>Dillon</surname>
   <given-names>JF</given-names>
  </name>, 
  <name>
   <surname>Gschwantler</surname>
   <given-names>M</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy</article-title>. 
  <source>Int J Drug Policy</source>. 
  <year>2019</year>
  <month>4</month>;
  <volume>66</volume>:
  <fpage>73</fpage>–
  <lpage>9</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.drugpo.2019.01.011</pub-id>
  <?supplied-pmid 30735896?>
  <pub-id pub-id-type="pmid">30735896</pub-id>
 </mixed-citation>
</ref>
